**Topic**

**Item**

**Checklist item description**

**Reported on Line**

**CARE Checklist of information to include when writing a case report**

**Title 1** The diagnosis or intervention of primary focus followed by the words “case report” . . . . . . . . . . . . . . . . . . . . . . . . . . Page 1, line 1

**Key Words 2** 2 to 5 key words that identify diagnoses or interventions in this case report, including "case report" . . . Page 2, line 75

 P

**Abstract**

**( no references)**

**3a** Introduction: What is unique about this case and what does it add to the scientific literature? . . . . . . . . . . . . . . . . Page 2, line 50

**3b** Main symptoms and/or important clinical findings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Page 2, line 60

**3c** The main diagnoses, therapeutic interventions, and outcomes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Page 2, line 61

**3d** Conclusion—What is the main “take-away” lesson (s) from this case? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Page 2, line 71

 P

**Introduction 4** One or two paragraphs summarizing why this case is unique (**may include references**) . . . . . . . . . . . . Page 3, line 96

**Patient Information 5a** De-identified patient specific information. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Page 4, line 122

**5b** Primary concerns and symptoms of the patie nt. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Page 4, line 123

**5c** Medical, family, and psycho- social history including relevant genetic information . . . . . . . . . . . . . . . . . Page 4, line 128

**5d** Relevant past interventions with outcomes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Page 4, line 126

 P

**Clinical Findings**

**6** Describe significant physical examination (PE) and important clinical findings. . . . . . . . . . . . . . . . . . . . . . . Page 4, line 128

**Timeline**

**7**

Historical and current information from this episode of care organized as a timeline . . . . . . . . . . . . . . . N/A

 N

**Diagnostic**

**Assessment**

**Therapeutic**

**Intervention**

**Follow-up and**

**Outcomes**

**Discussion**

**8a** Diagnostic testing (such as PE, laboratory testing, imaging, surveys). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Page 4, 130

**8b** Diagnostic challenges (such as access to testing, financial, or cultural) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . N/A

**8c** Diagnos is ( including other diagnoses considered) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Page 5, line 137

1. **d** Prognos is (such as staging in oncology) where applicable . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Page 4, line 135
2. **a** Types of therapeutic intervention (such as pharmacologic, surgical, preventive, self-care) . . . . . . . . . . . . . . . . . . . . Page 6, line 182

**9b** Administration of therapeutic intervention (such as dosage, strength, duration) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . N/A

1. **c** Changes in therapeutic intervention (with rationale) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . N/A
2. **a** Clinician and patient-assessed outcomes (if available) . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . Page 6, line 193

**10b** Important follow-up diagnostic and other test results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Page 6, line 198

**10c** Intervention adherence and tolerability (How was this assessed?) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . N/A

1. **d** Adverse and unanticipated events . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . N/A
2. **a** A scientific discussion of the strengths AND limitations associated with this case report . . . . . . . . . . . . . . . . . . . . . . . Page 7, line 210

**11b** Discussion of the relevant medical literature **with references**. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Page 12/13

**11c** The scientific rationale for any conclusions (including assessment of possible causes) . . . . . . . . . . . . . . . . . . . . . . . .

**11d** The primary “take-away” lessons of this case report (without references) in a one paragraph conclusion . . . . . . . Page 9, line 283

 Page

**Patient Perspective 12** The patient should share their perspective in one to two paragraphs on the treatment(s) they received . . . . . . . . N/A

**Informed Consent 13** Did the patient give informed consent? Please provide if requested . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . **Yes**